CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to test the safety and efficacy of ramucirumab in combination
with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial
sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol
which is a platform to accelerate the development of new treatments for pediatric and young
adult participants with cancer. Your participation in this trial could last 12 months or
longer, depending on how you and your tumor respond.